Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 3, 1999, Pages 343-359

  Esmon, Charles T ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Coagulation; Cytokines; Inflammation; Protein C pathway; Sepsis

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTITHROMBIN; CELL RECEPTOR; COMPLEMENT; CYTOKINE; ENDOTOXIN; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; BABOON; BLOOD CLOTTING; BLOOD FLOW; CATHETERIZATION; CELL CULTURE; CELL SURFACE; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; FIBROBLAST; HEMOSTASIS; HUMAN; INFLAMMATION; MONOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPOIESIS; THROMBOGENESIS; THROMBOSIS; TISSUE CULTURE; VASCULAR ENDOTHELIUM;

EID: 0033504250     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0029     Document Type: Article

References (86)

1. Zwaal R FA, Schroit A J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 89:1997;1121-1132.
2. Mann K G, Nesheim M E, Church W R. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 76:1990;1-16.
3. Esmon C T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. Journal of Biological Chemistry. 264:1989;4743-4746.
4. Stearns-Kurosawa D J, Kurosawa S, Mollica J S. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proceedings of the National Academy of Sciences of the USA. 93:1996;10212-10216.
5. Xu J, Esmon N L, Esmon C T. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. Journal of Biological Chemistry. 274:1999;6704-6710.
6. R506Qby activated protein C. Journal of Biological Chemistry. 270:1995;27852-27858.
7. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. Journal of Biological Chemistry. 269:1994;18735-18738.
8. Beutler B, Milsark I W, Cerami A C. Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effect of endotoxin. Science. 229:1985;869-871.
9. Brox J H, Osterud B, Bjorklid E. Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets. British Journal of Haematology. 57:1984;239-246.
10. Bevilacqua M P, Pober J S, Majeau G R. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. Journal of Experimental Medicine. 160:1984;618-623.
11. Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. Journal of Experimental Medicine. 163:1986;740-745.
12. Bach R R. Initiation of coagulation by tissue factor. Critical Reviews in Biochemistry and Molecular Biology. 23:1988;339-368.
13. Edgington T S, Mackman N, Brand K. The structural biology of expression and function of tissue factor. Thrombosis and Haemostasis. 66:1991;67-79.
14. Morrissey J H, Drake T A. Procoagulant response of the endothelium and monocytes. Schlag G, Redl H. Pathophysiology of Shock, Sepsis and Organ Failure. 1993;564-574 Springer-Verlag, Berlin.
15. Esmon C T. Protein S and protein C: biochemistry, physiology, and clinical manifestation of deficiencies. Trends in Cardiovascular Medicine. 2:1992;214-220.
16. McEver R P. GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium. Journal of Cellular Biochemistry. 45:1991;156-161.
17. Bevilacqua M P. Endothelial-leukocyte adhesion molecules. Annual Review of Immunology. 11:1993;767-804.
18. Boehme M WJ, Deng Y, Raeth U. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: in vivo and in vitro studies. Immunology. 87:1996;134-140.
19. Drake T A, Morrissey J H, Edgington T S. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. American Journal of Pathology. 134:1989;1087-1097.
20. Yamamoto M, Nakagaki T, Kisiel W. Tissue factor-dependent autoactivation of human blood coagulation factor VII. Journal of Biological Chemistry. 267:1992;19089-19094.
21. Neuenschwander P F, Fiore M M, Morrissey J H. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes: implications of a two-dimensional enzyme kinetic mechanism. Journal of Biological Chemistry. 268:1993;21489-21492.
22. Bach R, Rifkin D B. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proceedings of the National Academy of Sciences of the USA. 87:1990;6995-6999.
23. Comfurius P, Senden J MG, Tilly R HJ. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochimica et Biophysica Acta. 1026:1990;153-160.
24. Bevers E M, Comfurius P, Zwaal R FA. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Reviews. 5:1991;146-154.
25. Rapaport S I. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood. 73:1989;359-365.
26. Broze G J Jr, Girard T J, Novotny W F. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry. 29:1990;7539-7546.
27. Huang Z -F, Higuchi D, Lasky N. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood. 90:1997;944-951.
28. Shigematsu Y, Miyata T, Higashi S. Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa. Journal of Biological Chemistry. 267:1992;21329-21337.
29. Adcock D M, Brozna J, Marlar R A. Proposed classification and pathologic mechanisms of prupura fulminans and skin necrosis. Seminars in Thrombosis and Hemostasis. 16:1990;333-340.
30. Dreyfus M, Magny J F, Bridey F. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. New England Journal of Medicine. 325:1991;1565-1568.
31. Smith O P, White B, Vaughan D. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet. 350:1997;1590-1593.
32. Walsh L J, Trinchieri G, Waldorf H A. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proceedings of the National Academy of Sciences of the USA. 88:1991;4220-4224.
33. Bertina R M, Koeleman B PC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
34. Svensson P J, Dahlback B. Novel mechanism for thrombosis characterized by poor anticoagulant response to activated protein C constitutes a major cause of thrombophilia. Thrombosis and Haemostasis. 69:1993;999.
35. Esmon C T, Taylor F B Jr, Snow T R. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thrombosis and Haemostasis. 66:1991;160-165.
36. Dahlback B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thrombosis and Haemostasis. 66:1991;49-61.
37. Burstein S A. Cytokines, platelet production and hemostasis. Platelets. 8:1997;93-104.
38. Heeb M J, Mosher D, Griffin J H. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood. 73:1989;455-461.
39. Scully M F, Toh C H, Hoogendoorn H. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α1-antitrypsin and α2-macroglobulin, in patients with disseminated intravascular coagulation. Thrombosis and Haemostasis. 69:1993;448-453.
40. Conway E M, Rosenberg R D. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Molecular and Cellular Biology. 8:1988;5588-5592.
41. Lentz S R, Tsiang M, Sadler J E. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanisms. Blood. 77:1991;543-550.
42. Moore K L, Esmon C T, Esmon N L. Tumor necrosis factor leads to internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 73:1989;159-165.
43. Camera M, Giesen P LA, Fallon J. Cooperation between VEGF and TNF-α is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;531-537.
44. Matsuda J, Gohchi K, Kawasugi K. Inhibitory activity of anti-beta2-glycoprotein I antibody on factor Va degradation by activated-protein C and its cofactor protein S. American Journal of Hematology. 49:1995;89-91.
45. Solberg S, Osterud B, Larsen T. Lack of ability to synthesize tissue factor by endothelial cells in intact human saphenous veins. Blood Coagulation and Fibrinolysis. 1:1990;595-600.
46. Drake T A, Cheng J, Chang A. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal E. coli sepsis. American Journal of Pathology. 142:1993;1458-1470.
47. Laszik Z, Carson C W, Nadasdy T. Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy. Laboratory Investigations. 70:1994;862-867.
48. Labarrere C A, Esmon C T, Carson SD. Concordant expression of tissue factor and Class II MHC antigens in human placental endothelium. Placenta. II:1990;309-318.
49. Hancock W W, Tanaka K, Salem H H. TNF as a mediator of cardiac transplant rejection, including effects on the intragraft protein C/protein S/thrombomodulin pathway. Transplantation Proceedings. 23:1991;235-237.
50. Faust, S, N, Heyderman, R, S, Harrison, O, Molecular mechanisms of thrombosis in meningococcal septicaemia: the role of the protein C pathway in vivo, 1999.
51. Glaser C B, Morser J, Clarke J H. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. Journal of Clinical Investigation. 90:1992;2565-2573.
52. Key N S, Vercellotti G M, Esmon N L. Neutrophils enhance procoagulant effects of tumor necrosis factor on endothelium by accelerating thrombomodulin loss: role in endotoxin shock. Clinical Research. 37:1989;601a.
53. Ohdama S, Matsubara O, Aoki N. Plasma thrombomodulin in Wegener's granulomatosis as an indicator of vascular injuries. Chest. 106:1994;666-671.
54. Takano S, Kimura S, Ohdama S. Plasma thrombomodulin in health and diseases. Blood. 76:1990;2024-2029.
55. Topham M K, Garveth H J, McIntyre T M. Human endothelial cells regulate polymorphonuclear leukocyte degranulation. FASEB Journal. 12:1999;733-746.
56. Palabrica T, Lobb R, Furie B C. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 359:1992;848-851.
57. Yang J, Furie B C, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thrombosis and Haemostasis. 81:1999;1-7.
58. 2 +signals in J82 cells, transfected COS-1 cells, madin-darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. Journal of Biological Chemistry. 270:1995;4650-4660.
59. Sandberg H, Bode A P, Dombrose F A. Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3. Thrombosis Research. 39:1985;63-79.
60. Sims P J, Wiedmer T, Esmon C T. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott Syndrome: an isolated defect in platelet procoagulant activity. Journal of Biological Chemistry. 264:1989;17049-17057.
61. Ando B, Wiedmer T, Hamilton K K. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. Journal of Biological Chemistry. 263:1988;11907-11914.
62. Holme P A, Solum N O, Brosstad F. Clinical significance of platelet-derived microvesicles, demonstration of their presence in patients suffering from disseminated intravascular coagulation (DIC). Thrombosis and Haemostasis. 69:1993;1198.
63. Esmon C T. Cell mediated events that control blood coagulation and vascular injury. Annual Review of Cell Biology. 9:1993;1-26.
64. Miletich J P, Broze G J Jr. β Protein C is not glycosylated at asparagine 329: the rate of translation may influence the frequency of usage at asparagine-X-cysteine sites. Journal of Biological Chemistry. 265:1990;11397-11404.
65. Hung D T, Wong Y H, Vu T -KH. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. Journal of Biological Chemistry. 267:1992;20831-20834.
66. Kahn M L, Zheng Y -W, Huang W. A dual thrombin receptor system for platelet activation. Nature. 394:1998;690-694.
67. Altieri D C, Stamnes S J. Protease-dependent T cell activation: ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation. Cellular Immunology. 155:1994;372-383.
68. de Bont E SJM, Martens A, van Raan J. Tumor necrosis factor-alpha, interleukin-1β, and interleukin-6 plasma levels in neonatal sepsis. Pediatric Research. 33:1993;380-383.
69. Michie H R, Manogue K R, Spriggs D R. Detection of circulating tumor necrosis factor after endotoxin administration. New England Journal of Medicine. 318:1988;1481-1486.
70. Bauer K A, ten Cate H, Barzegar S. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 74:1989;165-172.
71. Dvorak H F, Van DeWater L, Bitzer A M. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Research. 43:1983;4434-4441.
72. Van DeWater L, Tracy P B, Aronson D. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Research. 45:1985;5521-5525.
73. Powars D, Larsen R, Johnson J. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clinical Infectious Diseases. 17:1993;254-261.
74. Hinshaw L B, Tekamp-Olson P, Chang A CK. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF-alpha). Circulatory Shock. 30:1990;279-292.
75. Taylor F B Jr, Chang A, Esmon C T. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. Journal of Clinical Investigation. 79:1987;918-925.
76. Taylor F, Chang A, Ferrell G. C4b-binding protein exacerbates the host response to Escherichia coli. Blood. 78:1991;357-363.
77. Hancock W W, Grey S T, Hau L. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation. 60:1995;1525-1532.
78. Grey S T, Tsuchida A, Hau H. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. Journal of Immunology. 153:1994;3664-3672.
79. Wakefield T W, Wrobleski S K, Sarpa M S. Deep venous thrombosis in the baboon generated through protein C inhibition. Journal of Vascular Surgery. 14:1991;588-598.
80. Taylor F B Jr, He S E, Chang A CK. Infusion of phospholipid vesicles amplifies the local thrombotic response to TNF and anti-protein C into a consumptive response. Thrombosis and Haemostasis. 75:1996;578-584.
81. Zentella A, Manogue K, Cerami A. The role of cachectin/TNF and other cytokines in sepsis. Sturk A. Bacterial Endotoxins: Cytokine Mediators and New Therapies for Sepsis. 1991;9-24 Wiley-Liss Inc, Somerset.
82. Feinberg B, Kurzrock R, Talpaz M. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. Journal of Clinical Oncology. 6:1988;1328-1334.
83. Whitehead R P, Fleming T, Macdonald J S. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. Journal of Biological Response Modifiers. 9:1990;588-591.
84. Gerson W T, Dickerman J D, Bovill E G. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics. 91:1993;418-422.
85. Esmon C T, Schwarz H P. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends in Cardiovascular Medicine. 5:1995;141-148.
86. Schneiderman J, Loskutoff D J. Plasminogen activator inhibitors. Trends in Cardiovascular Medicine. 1:1991;99-102.